ClinicalTrials.gg
RecruitingNCT06605521Updated Sep 20, 2024

To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients

An observational study in Locally Advanced Breast Cancer, sponsored by Henan Cancer Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-20.

Sponsored by Henan Cancer Hospital · Observational

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Breast Neoplasms by Henan Cancer Hospital — 29 open to participants now, 32 under way, 3 of them phase 3. Breast Neoplasms · Henan Cancer Hospital.

Started
2023
with 3 others
Observational
5 of 45
4 open now
Primary completion
2027-04
later than 15 of 31 live
Registered
26th of 45
by date

Among the 45 studies in Breast Neoplasms by Henan Cancer Hospital, this one is one of 4 that started in 2023, is one of 5 observational ones, reaches primary completion later than 15 of the 31 other live ones, and was the 26th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

29 of the 45 studies in Breast Neoplasms by Henan Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

23 more — sign in →

By country, each count listing its studies:

All 29 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 80 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Breast Neoplasms by Henan Cancer Hospital, or all of them as a file.
02

Study summary

For newly diagnosed ISLNM breast cancer, on the basis of effective treatment of the new auxiliary system, the optimal local treatment of the supraclavicular region remains controversial. Although guidelines such as NCCN recommend simple clavicular radiation therapy, there are studies suggesting that supraclavicular lymph node dissection can improve prognosis, and many hospitals in China are still accustomed to performing supraclavicular lymph node dissection. Therefore, ipsilateral supraclavicular lymph node dissection is the first time to diagnose ipsilateral supraclavicular lymph node metastasis of breast cancer. The effectiveness and safety of (stage IIIc) treatment still require prospective research to confirm.This project is a prospective, multicenter, non-interference real world study. In the real world study, the investigators evaluated the efficacy and safety of ipsilateral supraclavicular lymph node dissection in the treatment of initially diagnosed ipsilateral supraclavicular lymph node metastasis breast cancer patients.

Read the detailed description

For newly diagnosed ISLNM breast cancer, on the basis of effective treatment of the new auxiliary system, the optimal local treatment of the supraclavicular region remains controversial. Although guidelines such as NCCN recommend simple clavicular radiation therapy, there are studies suggesting that supraclavicular lymph node dissection can improve prognosis, and many hospitals in China are still accustomed to performing supraclavicular lymph node dissection. Therefore, ipsilateral supraclavicular lymph node dissection is the first time to diagnose ipsilateral supraclavicular lymph node metastasis of breast cancer. The effectiveness and safety of (stage IIIc) treatment still require prospective research to confirm.This project is a prospective, multicenter, non-interference real world study. In the real world study, the investigators evaluated the efficacy and safety of ipsilateral supraclavicular lymph node dissection in the treatment of initially diagnosed ipsilateral supraclavicular lymph node metastasis breast cancer patients.

The main endpoint of the study was recurrence free survival on the ipsilateral clavicle. The secondary study endpoint is disease-free survival; Ipsilateral supraclavicular relapse-free survival; Rregional lymph node relapse-free survival; Overall survival; Security; The incidence of upper limb lymphedema; Patient's quality of life.

03

Conditions studied

  • Locally Advanced Breast Cancer

Browse trials for

Keywords

  • Supraclavicular lymph node dissection
  • breast cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

cT1-4N3M0 breast cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients aged ≤ 80 years old.
  2. score 0-1 points;
  3. Breast cancer meets the following criteria: diagnosed as invasive breast cancer, known ER, PR, , KI67 status, pathologically diagnosed as ipsilateral supraclavicular lymph node (both cytology and histopathology);
  4. Estimated patient survival time exceeding three months;
  5. No obvious for surgery or radiotherapy;
  6. The researcher judged that they were able to comply with the research protocol.
  7. Those who participate in other clinical trials (including intervention or non intervention studies) at the same time and are judged by the researchers not to affect the research protocol can be enrolled normally.
  8. Voluntarily participate in this study and sign an form.

Exclusion criteria

Exclusion Criteria:

  1. Stage IV () breast cancer;
  2. Bilateral breast cancer;
  3. Received radiotherapy and surgical treatment (excluding local puncture) for ipsilateral supraclavicular metastatic lymph nodes before enrollment;
  4. History of breast cancer or other malignant tumors, but excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma;
  5. Individuals with severe primary diseases such as cardiovascular, cerebrovascular, liver, and kidney that are difficult to tolerate surgery or radiation therapy;
  6. Having a history of immunodeficiency, including testing positive, or having other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation;
  7. Suffering from severe comorbidities or other comorbidities that may interfere with the planned treatment, or any other circumstances in which the researcher deems the patient unsuitable to participate in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Subclavian lymph node dissection+radiotherapy group

    Subclavian lymph node dissection+radiotherapy

    Procedure: Subclavian lymph node dissection+radiotherapy

  • Simple clavicular region radiotherapy group

    Simple clavicular region radiotherapy

    Procedure: Simple clavicular region radiotherapy

Interventions

  • ProcedureSubclavian lymph node dissection+radiotherapy

    The patient grouping is determined jointly by the researchers and participants, and patients in Group A are selected for supraclavicular lymph node dissection and radiotherapy.

    Also known as: experimental group

  • ProcedureSimple clavicular region radiotherapy

    If the patient chooses Group B treatment plan, they will receive simple clavicle area radiotherapy.

    Also known as: control group

06

What researchers measure

Primary outcomes

  1. Intraclavicular recurrence free survival in group A patients

    The time from surgery to ipsilateral supraclavicular fossa recurrence or last follow-up.

    Time frame: 5th year after surgery

Secondary outcomes

  1. Disease-Free Survival

    The time from surgery to the occurrence of recurrence, metastasis, or last follow-up.

    Time frame: 5th year after surgery

  2. Intraclavicular recurrence free survival in group B patients

    The time from surgery to ipsilateral supraclavicular fossa recurrence or last follow-up

    Time frame: 5th year after surgery

  3. Regional lymph node recurrence free survival in group A/B patients

    The time from surgery to the occurrence of regional lymph node recurrence, metastasis, or last follow-up

    Time frame: 5th year after surgery

  4. Overall survival of patients in Group A/B

    The time from surgery to patient death or last follow-up

    Time frame: 5th year after surgery

  5. Number of adverse events

    Complications related to surgery and radiotherapy

    Time frame: through study completion, an average of 2 year

  6. The incidence of upper limb lymphedema in group A/B patients at 2 years after surgery

    Measure the circumference using the circumference method, with the styloid process of the ulna as the starting point, spaced 10cm apart and measured up to 40cm.

    Time frame: 2th year after surgery

  7. Patient's quality of life

    Evaluate using the EORTC-QLQ-C30 V3 (European Organization of Research and treatment of Cancer-Questionnaire of Life Quality-C30 Version 3)scale.EORTC-QLQ-C30 V3 is the core scale of the quality of life measurement system developed by the European Organization for Research and Treatment of Cancer (EORTC) for cancer patients. The original scores of each item in the scale need to be converted into standardized scores ranging from 0 to 100 using linear formulas. The higher the scores of each functional dimension, the better the functional status; The higher the score of the symptom scale and individual items, the more obvious the symptoms and the poorer the quality of life.

    Time frame: 2th year after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Apr 2027, 48 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 48 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2024
First posted
Sep 20, 2024
StartActual
Apr 4, 2023
Primary completionEst.
Apr 4, 2027
CompletionEst.
Apr 4, 2027
Last update
Sep 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06605521
Responsible party
Sponsor
First posted
Sep 20, 2024
Start date
Apr 4, 2023
Primary completion
Apr 4, 2027 (estimated)
Completion
Apr 4, 2027 (estimated)
Last update
Sep 20, 2024

Study contacts

xiuchun Chen
Contact
zlyychenxiuchun3921@zzu.edu.cn
0371-65587405
Minhao Lv
Contact
zlyylvminhao2789@zzu.edu.cn
0371-65587405
xiuchun Chen
study chair · Henan Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion